Management and Treatment of Recurrent Epithelial Ovarian Cancer
Management and Treatment of Recurrent Epithelial Ovarian Cancer
复制标题
DOI：
10.1016/j.hoc.2018.07.005
复制
发表时间：
2018-12-01
影响因子：
2.4
通讯作者：
Rauh-Hain, Jose Alejandro
中科院分区：
文献类型：
--
作者：
Armbruster, Shannon;Coleman, Robert L.;Rauh-Hain, Jose Alejandro
Most women with advanced epithelial ovarian cancer will experience many episodes of recurrent disease with progressively shorter disease-free intervals. For women whose disease continues to respond to platinum based drugs, the disease can often be controlled for 5 years or more. Enormous progress has been made in the management of this disease, and new targeted treatments such as antiangiogenic drugs, poly(adenosine diphosphate-ribose) polymerase inhibitors, and immune checkpoint inhibitors offer potential for improved survival. A variety of combination strategies are being evaluated to leverage these agents. The role of secondary cytoreduction remains a topic of active investigation.
